Form 4: Enanta Pharmaceuticals Chief Medical Officer Awarded Stock Options

Enanta Pharmaceuticals' Chief Medical Officer, Scott T. Rottinghaus, was granted 87,000 stock options on November 27, 2024.

Summary

• Scott T. Rottinghaus, the Chief Medical Officer of Enanta Pharmaceuticals, was granted 87,000 stock options on November 27, 2024.
• The options have an exercise price of $8.83 per share.
• The options vest quarterly over four years from the grant date, meaning they become exercisable in stages over time.
• The options expire on November 27, 2034.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management interests with shareholders. There is no indication of any negative sentiment.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to incentivize performance and retain key talent.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotechnology and pharmaceutical industries.
• The vesting schedule of four years is typical for such grants, aligning with long-term value creation.
• The exercise price is likely based on the current market value of the company's stock at the time of the grant.

Stakeholder Impact

• The stock option grant may be viewed positively by shareholders as it incentivizes the Chief Medical Officer to contribute to the company's long-term success.
• The grant does not have any immediate impact on employees, customers, suppliers or creditors.

Key Dates

Keywords

stock options, executive compensation, Enanta Pharmaceuticals, Scott T. Rottinghaus, Chief Medical Officer, equity, vesting